Showing 5671-5680 of 5909 results for "".
- Permanent J Code Issued for Avedro’s Photrexa Drug Formulationshttps://modernod.com/news/permanent-j-code-issued-for-avedros-photrexa-drug-formulations/2479654/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) issued a product-specific J code, J2787, for Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution). These Photrexa formulations are the onl
- Oculis Appoints New Members of Senior Management Teamhttps://modernod.com/news/oculis-appoints-new-members-of-senior-management-team/2479655/Oculis announced the appointments of Fabio Baschiera, PharmD, MPh, PhD, as Vice President of Clinical Development, and Louie-Anne Gauthier, M.Sc., as Vice President of Strategic Marketing, Business Development and Licensing. “We are delighted to welcome Fabio and Louie-Anne to the Oculis m
- Georgia Eye Associates Affiliates with EyeSouth Partnershttps://modernod.com/news/georgia-eye-associates-affiliates-with-eyesouth-partners/2479657/EyeSouth Partners has announced that it has completed a strategic partnership with Georgia Eye Associates, expanding its presence into the Lawrenceville and northeast Atlanta regions. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower
- Acuvue Oasys with Transitions Light Intelligent Technology Named Among TIME’s ‘Best Inventions of 2018’https://modernod.com/news/acuvue-oasys-with-transitions-light-intelligent-technology-named-among-times-best-inventions-of-2018/2479661/TIME has selected Acuvue Oasys with Transitions Light Intelligent Technology as one of the ‘Best Inventions of 2018,’ in its annual round-up spotlighting groundbreaking innovations worldwide. The development of Acuvue Oasys with Transitions has created and defined an entirely new cate
- Envision Research Institute Announces Search for Post Doctoral Fellows to Study Low Visionhttps://modernod.com/news/envision-research-institute-announces-search-for-post-doctoral-fellows-to-study-low-vision/2479664/The Gigi & Carl Allen Envision Research Institute (ERI) is now calling for letters of intent to apply for its next round of postdoctoral research fellowships. Launched in 2015 with a goal to restore function to those who are blind and visually impaired, the ERI provides access to funds, facil
- Eyepatch With Dissolvable Needles Used to Treat Eye Diseasehttps://modernod.com/news/eyepatch-with-dissolvable-needles-used-to-treat-eye-disease/2479667/A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases, according to a report in Medical Xpress.
- New Melanoma Treatments Do Not Supplant Surgery as First-Line Therapyhttps://modernod.com/news/new-melanoma-treatments-do-not-supplant-surgery-as-first-line-therapy/2479670/Although several new melanoma treatments have shown promise, none replaces surgery as the primary therapy yet, according to updated guidelines from the American Academy of Dermatology (AAD), as reported in Reuters Health. “Su
- Eyegate Pharma Announces Positive Results in Second PRK Studyhttps://modernod.com/news/eyegate-pharma-announces-positive-results-in-second-prk-study/2479671/EyeGate Pharmaceuticals announced topline data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage corneal epithelial defects in patients following photorefractive keratectomy (PRK) surgery, compared to current standard of care. “T
- Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet AMDhttps://modernod.com/news/ophthotech-announces-results-from-phase-2a-safety-trial-of-zimura-in-combination-with-lucentis-in-wet-amd/2479673/Ophthotech announced the results from its phase 2a safety trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combinat
- Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Diseasehttps://modernod.com/news/acucela-initiates-phase-3-study-of-emixustat-addressing-patients-with-stargardt-disease/2479674/Acucela announced that on November 7, 2018, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (emixustat), in subjects with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, a